Contract development and manufacturing organization (CDMO) Grand River Aseptic Manufacturing (GRAM) disclosed on Thursday that it has been selected by the US Department of Health and Human Services and the US Department of Defense to support the expansion of the nation's capacity for manufacturing and distributing vaccines or therapeutics related to the COVID-19 pandemic.
By providing the capacity to perform advanced aseptic fill and finish services -- the last two steps in the manufacturing process for vaccines or other therapeutics -- GRAM is helping to ensure that the country will have sufficient domestic supply to make life-saving biopharmaceutical products available as quickly as possible.
Through this public-private partnership, the US Government is reserving fill/finish capacity on a commercial filling line for use by federal partners that are developing COVID-19 vaccines or therapeutic treatments.
GRAM will utilize its new 60,000 sq ft large-scale fill/finish facility located in Grand Rapids, Michigan to support the effort. In total, the CDMO has three manufacturing facilities and more than 100,000 sq ft of production space. GRAM's large-scale fill/finish facility was designed for growth and contains additional space to add more equipment and fill suites as demand continues.
As well as supporting the Government's Operation Warp Speed efforts and the COVID-19 pandemic response, GRAM's capacity increases US preparedness for future public health emergencies.
EpiVax introduces AI-enhanced models for immunogenicity prediction
Pfizer and BioNTech granted FDA approval for XFG-adapted COVID-19 vaccine
4basebio announces strategic collaboration with Genezen
Charles River and Medigen collaborate on next-generation enterovirus vaccine development
Piramal Pharma acquires controlling stake in Yapan Bio
Innorna Nominated for 2026 Prix Galien USA Best Startup Award
Sanofi's MenQuadfi receives EU approval for infants from six weeks
Evaxion to present three-year cancer vaccine data at ESMO Congress 2026
Evaxion presents new preclinical data on cytomegalovirus vaccine EVX-V1
Northwest Biotherapeutics presents on propensity score matching at BNOS 2026
Taiwan biomedical startups hold over 100 business meetings at BIO 2026
SK bioscience to lead Gates Foundation-funded ROTOR project
Anixa Biosciences' breast cancer vaccine technology granted first Korean patent
Transgene expands myvac platform into non-small cell lung cancer with TG4070